Novel PCSK9 Inhibitor Reduced LDL by 50%

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

Related Keywords

South Africa ,United States ,Johannesburg ,Gauteng ,American ,Eric Klug ,American College Of Cardiology ,Division Of Cardiology ,University Of The Witwatersrand ,European Society Of Cardiology ,Prevention Of Cardiovascular Disease Council ,Virginia Commonwealth University School Of Pharmacy ,American Heart Association ,Drug Administration ,American College ,Scientific Session ,European Society ,Virginia Commonwealth University School ,Cardiovascular Disease Council ,